Treatment Of Patients With Advanced Biliary Tract Cancer With Either Oxaliplatin, Gemcitabine, And Capecitabine Or Cisplatin And Gemcitabine-A Randomized Phase Ii Trial

This study is an investigator-initiated randomized phase II trial focusing on the treatment of advanced biliary tract cancer with either oxaliplatin 50 mg/m(2)and gemcitabine 1000 mg/m(2)on day 1 in a two-week cycle with capecitabine 650 mg/m(2)twice-daily continuously or cisplatin 25 mg/m(2)and gemcitabine 1000 mg/m(2)on day 1 and day 8 in a three-week cycle. One-hundred patients were included. Forty-seven patients received oxaliplatin, gemcitabine, and capecitabine with a median progression-free survival (mPFS) of 5.7 months (95% CI 3.0-7.8) and a median overall survival (mOS) of 8.7 months (95% CI 6.5-11.2). Forty-nine patients received cisplatin and gemcitabine with a mPFS of 7.3 months (95% CI 6.0-8.7) and a mOS of 12.0 months (95% CI 8.3-16.7). This trial confirms a mOS of 12 months with cisplatin and gemcitabine, as found in earlier trials. With a superior tumor control rate of 79% vs. 60% (p= 0.045), a difference in the mPFS of 1.6 months (HR = 0.721,p= 0.1), and a difference in the mOS of 3.3 months (HR = 0.731,p= 0.1), cisplatin and gemcitabine should still be considered the standard first-line treatment for advanced biliary tract cancer.